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Dear Sir,
The RH genes RHD and RHCE encode two 
proteins that represent the clinically most important 
blood group system defined by the sequences of red 
cell membrane proteins. RHD and RHCE, encoding 
the Rh proteins (D and Cc/Ee, respectively), are 
organised in tandem on chromosome 1p34-p36 and 
probably derived from duplication of a common 
ancestral gene. Many RH genes carry point mutations, 
or have rearrangements and exchanges between 
RHD and RHCE which result from gene conversion 
events. RHCE encode hybrid proteins that have 
RhCE-specific amino acids in RhD, or RhD-specific 
residues in RhCE. These might generate new antigens 
in the Rh blood group system, and alter or weaken 
expression of the conventional antigens1,2.
Reduced expression of D antigen occurs in an 
estimated 0.2%-1% of Caucasians. Historically, red 
blood cell antigens that react with anti-D only after 
extended testing with the indirect antiglobulin test are 
called weak D. Weak D expression primarily results 
from single point mutations in RHD which encode 
amino acid changes predicted to be intracellular or in 
the transmembrane regions of RhD. These affect the 
efficiency of insertion, and, therefore, the quantity of 
RhD protein in the membrane, reflected in the reduced 
number of D antigen sites on the red blood cells. Red 
blood cells with partial D antigen type as D-positive, 
but individuals often produce anti-D when stimulated 
by transfusion or pregnancy. Some partial D, similar 
to weak D, result from point mutations in RHD that 
cause single amino acid changes. But, in contrast to 
weak D, these changes are located on the extracellular 
regions and alter or create new epitopes1,2.
Molecular methods for blood group genotyping 
became available more than 10 years ago and are 
useful methods to help to clarify immunogenetic 
doubts or to verify results3. Molecular RHD blood 
group typing is very efficient for managing donors 
and patients carrying any of the various molecular 
types of weak D and partial D. Weak D and partial 
D expression are caused by a large number of RHD 
alleles and variations of the antigen structure of 
RhD result either in a partial (partial D) or a weak 
D phenotype (weak D). Weak and partial D result in 
quantitative and qualitative changes in Rh protein 
expression respectively. The clinical relevance of 
these changes are, according to Flegel1,2, that weak 
D subjects belonging to weak type 1, 2, 3, 4.0, 4.1 
and 5 can be treated as Rh-positive and be transfused 
by Rh-positive red blood cells, while subjects with 
weak type 4.2-11 and 15 should be treated as Rh-
negative and transfused with Rh-negative red blood 
cells. Partial D can produce different protein epitope 
expression and, therefore, induce specific antibody 
production. In this situation, partial D subjects should 
be considered Rh-negative and transfused with Rh-
negative red blood cells1,2.
In our daily practice, D antigens are determined 
serological agglutination tests according to the 
guidelines of Italian Society for Transfusion Medicine 
and Immunohaematology4. In particular, during routine 
Rhesus tests, a microtitre plate-based assay employing 
two different anti-D (D-Rapid, clone RUM-1 IgM 
and D-Fast, clone IgM; Immucor Gamma, Immucor, 
Inc. Norcross, GA, USA) is used. Thereafter, the D 
negative samples are tested for Du with two different 
methods: a microtitre plate employing Anti-D Duo 
IgG-IgM (clone IgG/IgM clone Th28+MS26; Galileo 
Capture R ImmucorGamma) using solid phase capture 
and a gel matrix test  employing one anti-D (Id-Dia 
Clone Anti-D; DiaMed GmbH, Switzerland). If the 
result is positive, the samples are tested with a gel 
matrix direct antiglobulin assay. The serological 
analysis for allelic D variant is based on "Partial Rh 
Typing" (ImmucorGamma) using six monoclonal IgG 
antisera and Capture-R Select (ImmucorGamma) in a 
solid phase method.
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Molecular biology analysis is performed using 
commercial kits from BAGene Health Care GmbH 
(Weak D-TYPE; Partial D-TYPE; BAG Health Care 
GmbH, Germany). The basic material for typing 
with BAGene DNA-SSP kits is purified DNA from 
peripheral blood mononuclear cells. The test is based 
on sequence-specific primers (SSP) - polymerase 
chain reaction (PCR). BAGene Partial D-TYPE 
allows for the molecular genetic determination of 
partial D such as DII, DIII, DIV, DV, DVI, DVII, 
DAU, DBT, DFR, DHMi, DHMii, DNB and DHAR 
(Rh33)5, whereas BAGene Weak D-TYPE allows 
the molecular genetic determination of weak D types 
including 1, 2, 3, 4.0/4.1, 4.2, 5, 11, 15 and 175. Both 
methods are based on the fact that primer extension, 
and hence successful PCR, relies on an exact match 
at the 3'-end of both primers. Therefore, only if 
the primers entirely match the target sequence is 
amplification obtained; this is subsequently visualised 
by agarose gel electrophoresis. 
In 2010, a survey performed at our Unit, the 
Immunohaematology and Transfusion Medicine 
Unit of the "Paolo Giaccone" University Hospital 
in Palermo, revealed that out of 11 samples (from 
8 males and 3 females) analysed and regarded by 
preliminary analysis as weak D, only eight were 
confirmed by complete serological analysis as weak 
D, whereas the other three samples did not give 
satisfactory results. A genetic protocol was, therefore, 
used, which gave the results of D weak type 1/DCS, 
type 11/DCS, and 5/DAR respectively. On the basis 
of this outcome, we re-evaluated the eight patients 
assessed as weak D by serological analysis getting D 
weak type 5/DCS as the most frequent result. These 
results were not influenced by the patients' gender 
or age.
Given the strong immunogenicity of the D antigen 
and the high rate of immunisation of D-negative 
individuals after the transfusion of D-positive red 
blood cells, the determination of RHD alleles is of 
special significance1,2,5. Immunisation of D-negative 
individuals can occur following transfusions 
of D-positive red blood cells and in D-negative 
pregnant women carrying D-positive foetuses5. 
The aim of this study was to use a genetic protocol 
to confirm and/or clarify D antigen doubts in order 
to prevent immunisation of patients. At first glance, 
serological analysis for D weak appeared to be 
trustworthy regarding common D weak phenotypes 
whereas analysis of non-common phenotypes was 
less satisfactory. In particular, D weak type 5 was 
easily identifiable by serological analysis whereas D 
weak types 1 and 11 seemed to display lower antibody 
affinity and was, therefore, less well identified. 
With respect to this problem, the use of the genetic 
protocol was decisive for obtaining correct results. 
The evidence of D partial results was confirmed by 
the presence of DCS and DAR variants. The genetic 
resolution of these variants is, so far, limited, and 
these two results are, therefore, taken in the context 
of D-positive results. However, given the low number 
of samples screened, this study cannot be decisive 
and other samples need to be analysed.
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